ONO-4915
DrugSubcutaneous administration
NCT Number: NCT07823790
To evaluate the efficacy and safety of ONO-4915 in patients with primary Sjogren's disease
Trial opening soon.
Get Notified18 year–74 year
All sexes
Interventional
Phase 2
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Subcutaneous administration
Subcutaneous administration
Time frame: up to week 24
Patient-reported assessment of dryness, fatigue, and pain, each scored from 0 to 10. The total ESSPRI score is calculated as the mean of the three domain scores and ranges from 0 to 10, with higher scores indicating worse symptoms.
Time frame: up to week 32
Patient-reported assessment of dryness, fatigue, and pain, each scored from 0 to 10. The total ESSPRI score is calculated as the mean of the three domain scores and ranges from 0 to 10, with higher scores indicating worse symptoms.
Time frame: up to week 32
Each symptom is scored daily on a numerical scale, with higher scores indicating worse symptoms.
Time frame: up to week 32
Symptoms are evaluated across 12 organ/system domains using a 4-point scale (0 = no activity to 3 = severe activity). Each domain score is weighted according to its clinical importance, and the weighted scores are summed to yield a total score ranging from 0 to 123, with higher scores indicating greater disease activity.
Time frame: up to week 32
Time frame: up to week 32
Evaluated by physician on a numerical scale. Higher scores indicate worse symptoms.
Time frame: up to week 24
Time frame: up to week 24
Time frame: up to week 24
Time frame: up to week 32
Time frame: up to week 32
Time frame: up to week 24
Time frame: up to week 24
Time frame: up to week 32
Time frame: up to week 32
Time frame: up to week 24
Time frame: up to week 32
Time frame: up to week 32
Time frame: up to week 32
Time frame: up to week 32
Time frame: up to week 24
Time frame: up to week 32
Time frame: up to week 32
Time frame: up to week 32
Time frame: up to week 32
Time frame: up to week 32
Scores for the dryness, pain, and fatigue symptoms comprising the ESSPRI. Higher scores indicate worse symptom severity.
Time frame: up to week 32
Time frame: up to week 32
Time frame: up to week 32
Time frame: up to week 32
Time frame: up to week 32
Time frame: up to week 32
Time frame: up to week 24
Time frame: up to week 24
Time frame: up to week 24
Time frame: up to week 24
Time frame: up to week 24
Time frame: up to week 32
Time frame: up to week 32
Time frame: up to week 32
Contact information is provided by the study sponsor or research team.
International Clinical Trial Support Desk
CONTACT
+17162141777(Standard)
North America Clinical Trial Support Desk
CONTACT
+18665877745(Toll-Free)
Ono Pharmaceutical Co., Ltd.
Industry
A Phase II Multicenter, Placebo-controlled, Randomized, Double-blind, Parallel-group Study in Patients With Primary Sjogren's Disease to Evaluate the Efficacy and Safety of Subcutaneously Administered ONO-4915
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07732309
Arthritis, Arthritis, Rheumatoid
Bengbu, Anhui, China
View Trial DetailsNCT06392711
Arthritis, Arthritis, Rheumatoid
Madison, Wisconsin, United States
View Trial DetailsNCT07544394
Arthritis, Arthritis, Rheumatoid
Kahramanmaraş, Turkey (Türkiye)
View Trial DetailsNCT00740948
Arthritis, Arthritis, Rheumatoid
Brest, France
View Trial Details